In a report released today, Silvan Tuerkcan from JMP Securities maintained a Buy rating on Benitec Biopharma (BNTC – Research Report), with a price target of $4.00. The company’s shares closed yesterday at $0.19.
According to TipRanks, Tuerkcan is an analyst with an average return of -4.1% and a 33.70% success rate. Tuerkcan covers the Healthcare sector, focusing on stocks such as Relay Therapeutics, Exelixis, and Mirati Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Benitec Biopharma with a $4.00 average price target.
See the top stocks recommended by analysts >>
BNTC market cap is currently $6.1M and has a P/E ratio of -0.15.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Benitec Biopharma Ltd. engages in the development of proprietary therapeutic technology platform. It focuses on chronic and life-threatening human disease areas such as oncology, orphan disease, retinal disease, and infectious disease. The company was founded in 1997 and is headquartered in North Sydney, Australia.
Read More on BNTC:
